Cerespir Announces The Inauguration Of Its Clinical Advisory Board
2/21/2014 8:52:34 AM
NEW YORK, Feb. 21, 2014 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company developing the first-in-class microglial modulator CHF 5074 as a potential treatment for Alzheimer's disease (AD), today announced the inauguration of its Clinical Advisory Board (CAB). Rachelle Doody, MD, PhD, Baylor College of Medicine, is serving as Chair of the Board. The Advisory Board also includes Steven H. Ferris, PhD, New York University Langone Medical Center; Michael Grundman, MD, MPH, President and CEO, Global R&D Partners, LLC; Eric M. Reiman, MD, Executive Director, Banner Alzheimer's Institute; and Lon S. Schneider, MD, MS, Keck School of Medicine of USC.
Help employers find you! Check out all the jobs and post your resume.
comments powered by